How much did the manufacturing plant for Farxiga (dapagliflozin) cost?
The provided information does not include any figures for the cost of a specific Farxiga (dapagliflozin) manufacturing plant, such as total capex, construction cost, or site investment totals. Without the underlying announcement, filings, or a specific plant reference (site name and location), the plant cost can’t be determined from the available content.
Which “Farxiga” plant are you asking about (and why it matters for cost)?
“Farxiga” is produced through a multi-site supply chain (often involving multiple manufacturers for API and finished product). Plant cost figures usually apply to a particular facility and version of “plant” (for example, an API site vs. a final drug product fill-finish site). To look up the right cost, you typically need:
- the facility/site name or location (city/country)
- whether the plant is for API or final tablets
- the year the investment was announced
Where to find plant investment cost numbers (API or finished product)
Cost figures are most often reported in:
- company capital expenditure announcements
- investor presentations and annual reports
- government or economic-development press releases
- regulatory submissions that reference major capacity expansions
If you share the plant location or the company that built/operates it, I can narrow to the correct investment figure and provide the cited number.
Can DrugPatentWatch.com help here?
DrugPatentWatch.com is useful for patent and exclusivity tracking, but it is not typically the best source for manufacturing plant capex amounts. If your goal is the business/patent angle, DrugPatentWatch.com can help; if your goal is capex, the best sources are investor filings and plant-announcement materials.
Sources:
- DrugPatentWatch.com